Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by Wellington Management Group LLP

Wellington Management Group LLP trimmed its stake in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 15.1% in the fourth quarter, Holdings Channel reports. The fund owned 4,234,455 shares of the company’s stock after selling 751,521 shares during the period. Wellington Management Group LLP’s holdings in Syndax Pharmaceuticals were worth $55,979,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. R Squared Ltd purchased a new stake in shares of Syndax Pharmaceuticals during the fourth quarter worth approximately $26,000. Quantbot Technologies LP acquired a new position in Syndax Pharmaceuticals in the 3rd quarter valued at $49,000. Cape Investment Advisory Inc. raised its position in Syndax Pharmaceuticals by 157.1% during the 4th quarter. Cape Investment Advisory Inc. now owns 6,427 shares of the company’s stock worth $85,000 after buying an additional 3,927 shares during the last quarter. KBC Group NV lifted its stake in shares of Syndax Pharmaceuticals by 104.8% in the 4th quarter. KBC Group NV now owns 6,954 shares of the company’s stock worth $92,000 after acquiring an additional 3,559 shares during the period. Finally, E Fund Management Co. Ltd. boosted its holdings in shares of Syndax Pharmaceuticals by 14.4% in the fourth quarter. E Fund Management Co. Ltd. now owns 12,603 shares of the company’s stock valued at $167,000 after acquiring an additional 1,583 shares in the last quarter.

Insider Activity

In other news, CEO Michael A. Metzger sold 13,288 shares of the business’s stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $15.50, for a total value of $205,964.00. Following the completion of the transaction, the chief executive officer now owns 300,121 shares of the company’s stock, valued at $4,651,875.50. The trade was a 4.24 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Keith A. Goldan sold 3,777 shares of the firm’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $15.50, for a total transaction of $58,543.50. Following the sale, the chief financial officer now owns 90,746 shares in the company, valued at approximately $1,406,563. This trade represents a 4.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 21,683 shares of company stock worth $336,087 over the last three months. 4.10% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

SNDX has been the subject of a number of recent analyst reports. HC Wainwright restated a “buy” rating and issued a $51.00 price objective on shares of Syndax Pharmaceuticals in a research report on Tuesday, March 4th. JPMorgan Chase & Co. lifted their price target on Syndax Pharmaceuticals from $39.00 to $41.00 and gave the company an “overweight” rating in a research note on Thursday, March 20th. StockNews.com upgraded Syndax Pharmaceuticals to a “sell” rating in a research report on Wednesday. Scotiabank decreased their target price on shares of Syndax Pharmaceuticals from $18.00 to $16.00 and set a “sector perform” rating on the stock in a research report on Wednesday, January 8th. Finally, Citigroup cut their price target on shares of Syndax Pharmaceuticals from $45.00 to $42.00 and set a “buy” rating for the company in a report on Tuesday, March 4th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $36.20.

Syndax Pharmaceuticals Trading Down 9.7 %

NASDAQ:SNDX opened at $11.25 on Friday. The company has a market capitalization of $967.77 million, a P/E ratio of -3.10 and a beta of 0.92. The firm has a 50-day moving average price of $14.13 and a two-hundred day moving average price of $15.67. Syndax Pharmaceuticals, Inc. has a twelve month low of $11.09 and a twelve month high of $25.07.

Syndax Pharmaceuticals (NASDAQ:SNDX) last issued its quarterly earnings data on Monday, March 3rd. The company reported ($1.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.79). The company had revenue of $7.68 million during the quarter, compared to analysts’ expectations of $86.32 million. On average, equities research analysts predict that Syndax Pharmaceuticals, Inc. will post -3.72 earnings per share for the current year.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).